Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
AssigneeCadila Healthcare Limited
InventorsSunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
Life of this patent
Estimating the term…
Abstract
Stable pharmaceutical compositions and processes for making same for the treatment of psoriasis. The compositions may be nanoemulsions having nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. The compositions exhibit improved permeability and bioavailability.
Claims11
A stable topical pharmaceutical nanogel composition of clobetasol or a salt or ester thereof, the nanogel composition consisting of a nanoemulsion and a gel base, the nanoemulsion consisting of nano size droplets of clobetasol or a salt or ester thereof, 5% to 20% by weight of the composition of oils or lipids, 0.1% to 10% by weight of emulsifiers selected from a group consisting of ionic polysorbate surfactant, nonylphenol polyethylene glycol ethers, (alkylphenol-hydroxypolyoxyethylene), poly(oxy-1,2-ethanediyl), alpha-(4-nonylphenol)-omega-hydroxy-, branched, nonylphenol polyethylene glycol ether mixtures, phenoxypolyethoxyethanols and polymers thereof, different grades of brij, and sodium dodecyl sulfate, and one or more pharmaceutically acceptable excipients selected from the group consisting of initiators, pH adjusting agents, thickening agents, emollients, humectants, preservatives, antioxidants, and chelating agents.
A stable topical pharmaceutical nanogel composition of clobetasol or a salt or ester thereof and salicylic acid or a salt or ester thereof, the nanogel composition consisting of a nanoemulsion and a gel base, the nanoemulsion consisting of nano size droplets of clobetasol or a salt or ester thereof and salicylic acid or a salt or ester thereof, 5% to 20% by weight of the composition of oils or lipids, 0.1% to 10% by weight of emulsifiers selected from a group consisting of ionic polysorbate surfactant, nonylphenol polyethylene glycol ethers, (alkylphenol-hydroxypolyoxyethylene), poly(oxy-1,2-ethanediyl), alpha-(4-nonylphenol)-omega-hydroxy-, branched, nonylphenol polyethylene glycol ether mixtures, phenoxypolyethoxyethanols and polymers thereof, different grades of brij, and sodium dodecyl sulfate, and a pharmaceutically acceptable excipients selected from the group consisting of initiators, pH adjusting agents, thickening agents, emollients, humectants, preservatives, antioxidants, and chelating agents.
Dependencies are inferred from the claim text.